The Russian holding company Natsimbio (part of Rostec Group) will continue to develop a combined vaccine against influenza and COVID-19 with another partner and using another platform. Earlier, the cooperation with Artgen Biotech was suspended due to objections to the drug development process. However, as the Rostec press service told TASS, the difficulties will not affect the company’s plans, and it is going to apply for permission to conduct clinical trials in the near future. If the trials are successful, the vaccine will simplify the prevention of two infections, as a single vaccination can be used.
“Joint work with Artgen Biotech had to be suspended, as there were some objections on the drug development process by the partner. In accordance with the terms of the agreement, Artgen Biotech was to develop the drug and conduct preclinical trials, while Natsimbio was to conduct clinical trials and arrange the registration of the vaccine. Since the shortcomings have not been eliminated, the holding has decided not to start clinical trials,” Rostec explained.
The state corporation did not disclose the name of the new partner, adding that if the shortcomings are eliminated, cooperation with Artgen Biotech can be continued, including with regard to the supply of influenza virus antigens.
The vaccine being developed holds significant social and economic importance. It is expected that one vaccination will be enough to protect from the two diseases. Due to its dual action, it can lead to an increase in the effectiveness of preventon of influenza and COVID-19.
